IPO: Decipher Biosciences Advances Prostate Genomic Testing
Decipher Biosciences, a commercial-stage precision urology oncology company, has filed with the U.S. Securities and Exchange Commission (SEC) to raise to raise up to $100 million in an IPO. Decipher’s prostate cancer genomic testing products surface information about the underlying biology of a patient’s tumor. The company applies machine learning algorithms to help physicians improve … Read more